Traders purchased shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on weakness during trading hours on Wednesday. $48.48 million flowed into the stock on the tick-up and $35.59 million flowed out of the stock on the tick-down, for a money net flow of $12.89 million into the stock. Of all companies tracked, Alexion Pharmaceuticals had the 8th highest net in-flow for the day. Alexion Pharmaceuticals traded down ($1.37) for the day and closed at $130.36

A number of research analysts recently issued reports on ALXN shares. Leerink Swann reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a report on Friday, June 17th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $185.00 price target on shares of Alexion Pharmaceuticals in a report on Tuesday, August 16th. Jefferies Group reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a report on Sunday, May 29th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $221.00 price target (down from $228.00) on shares of Alexion Pharmaceuticals in a report on Tuesday, June 7th. Finally, SunTrust Banks Inc. cut their price target on Alexion Pharmaceuticals from $220.00 to $197.00 and set a “buy” rating for the company in a report on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $182.85.

The company’s 50 day moving average is $131.16 and its 200-day moving average is $135.82. The stock has a market cap of $29.23 billion, a PE ratio of 327.54 and a beta of 1.08.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing the consensus estimate of $1.17 by $0.04. The firm earned $753 million during the quarter, compared to the consensus estimate of $743.18 million. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. Alexion Pharmaceuticals’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.44 earnings per share. On average, equities analysts expect that Alexion Pharmaceuticals Inc. will post $4.65 earnings per share for the current fiscal year.

In other news, CEO David Hallal sold 332 shares of the firm’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $137.14, for a total transaction of $45,530.48. Following the completion of the transaction, the chief executive officer now directly owns 189,266 shares in the company, valued at $25,955,939.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Vikas Sinha sold 277 shares of the firm’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $37,987.78. Following the transaction, the chief financial officer now owns 178,463 shares of the company’s stock, valued at $24,474,415.82. The disclosure for this sale can be found here. Insiders own 4.41% of the company’s stock.

Institutional investors have recently modified their holdings of the company. FMR LLC increased its position in shares of Alexion Pharmaceuticals by 12.0% in the second quarter. FMR LLC now owns 18,745,795 shares of the biopharmaceutical company’s stock worth $2,188,759,000 after buying an additional 2,002,085 shares during the period. TIAA CREF Investment Management LLC increased its position in shares of Alexion Pharmaceuticals by 34.8% in the second quarter. TIAA CREF Investment Management LLC now owns 2,952,205 shares of the biopharmaceutical company’s stock worth $344,699,000 after buying an additional 762,010 shares during the period. Ameriprise Financial Inc. increased its position in shares of Alexion Pharmaceuticals by 13.7% in the second quarter. Ameriprise Financial Inc. now owns 6,025,775 shares of the biopharmaceutical company’s stock worth $703,575,000 after buying an additional 728,182 shares during the period. Thrivent Financial for Lutherans increased its position in shares of Alexion Pharmaceuticals by 9,454.4% in the second quarter. Thrivent Financial for Lutherans now owns 624,860 shares of the biopharmaceutical company’s stock worth $72,958,000 after buying an additional 618,320 shares during the period. Finally, Brown Advisory Inc. increased its position in shares of Alexion Pharmaceuticals by 23.6% in the second quarter. Brown Advisory Inc. now owns 3,047,631 shares of the biopharmaceutical company’s stock worth $355,841,000 after buying an additional 581,703 shares during the period. Institutional investors own 96.34% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.